Suchergebnisse - "Caminati, Marco"

PubPharm (18)

1

Safety of Biological Therapies for Severe Asthma : An Analysis of Suspected Adverse Reactions Reported in the WHO Pharmacovigilance Database

enthalten in: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy | 2024

von Cutroneo, P. | Arzenton, E. | Furci, F. | +7

2

Successful switching from mepolizumab to dupilumab in a patient with EGPA in remission phase and persistent nasal polyposis

enthalten in: Rheumatology (Oxford, England) | 2024

von Caminati, M. | Scarpieri, E. | Maule, M. | +4

3

Eosinophilic granulomatosis with polyangiitis onset in severe asthma patients on monoclonal antibodies targeting type 2 inflammation : Report from the European EGPA study group

enthalten in: Allergy | 2024

von Caminati, M. | Fassio, A. | Alberici, F. | +22

4

Long-Term Efficacy of Mepolizumab at 3 Years in Patients with Severe Asthma : Comparison with Clinical Trials and Super Responders

enthalten in: Biomedicines | 2023

von Bagnasco, D. | Nicola, S. | Testino, E. | +27

5

Benralizumab Efficacy in Late Non-Responders to Mepolizumab and Variables Associated with Occurrence of Switching : A Real-Word Perspective

enthalten in: Journal of clinical medicine | 2023

von Caminati, M. | Marcon, A. | Guarnieri, G. | +8

6

Sequential rituximab and mepolizumab in eosinophilic granulomatosis with polyangiitis (EGPA) : a European multicentre observational study

enthalten in: Annals of the rheumatic diseases | 2022

von Bettiol, A. | Urban, M. | Bello, F. | +39

7

One-year mepolizumab for Allergic bronchopulmonary aspergillosis : Focus on steroid sparing effect and markers of response

enthalten in: European journal of internal medicine | 2022

von Caminati, M. | Batani, V. | Guidolin, L. | +2

8

Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis : A European Multicenter Observational Study

enthalten in: Arthritis & rheumatology (Hoboken, N.J.) | 2022

von Bettiol, A. | Urban, M. | Dagna, L. | +92

9

Reply to "Mepolizumab in patients with eosinophilic granulomatosis with polyangiitis in remission : What is the right dose?"

enthalten in: The journal of allergy and clinical immunology. In practice | 2021

von Caminati, M. | Crisafulli, E. | Lunardi, C. | +6

CommentOn: J Allergy Clin Immunol Pract. 2021 Mar;9(3):1386-1388. - PMID 33011303

10

Mepolizumab 100 mg in severe asthmatic patients with EGPA in remission phase

enthalten in: The journal of allergy and clinical immunology. In practice | 2021

von Caminati, M. | Crisafulli, E. | Lunardi, C. | +6

CommentIn: J Allergy Clin Immunol Pract. 2021 Jul;9(7):2942-2943. - PMID 34246444